

## **Instructions for Authors** (updated on Feb. 6, 2025)

### **Submission**

MHC is the official journal of the Japanese Society for Histocompatibility and Immunogenetics (JSHI). The aim of this journal is to serve as a forum for the scientific information in the form of original and highquality papers in the field of major histocompatibility complex (MHC) and immunogenetics. Manuscripts, from basic to clinical research relating to MHC or immunogenetics, are accepted with the understanding that they are original unpublished works and are not being submitted elsewhere. Manuscripts should be written in Japanese or English. The first author and corresponding author must be members of JSHI, while it is preferable for the other co-authors also to be JSHI members.

Ethics: Clinical and basic studies using human subjects and specimens obtained from humans must adhere to the 1964 Helsinki Declaration (adapted by the 18<sup>th</sup> World Medical Assembly and amended by the 75<sup>th</sup> World Medical Assembly) and must be approved by the ethics review board of each participating institution. Furthermore, animal studies must adhere to such guidelines.

Conflict of interest: All the authors must clearly declare any conflicts of interest according to the guideline of JSHI (<https://jshi.smoosy.atlas.jp/ja/coi>). Further information is available upon request.

Declaration of no research misconduct: All the authors must declare not to have engaged in any research misconduct according to the guideline of JSHI ([https://jshi.smoosy.atlas.jp/ja/instruction\\_for\\_authors](https://jshi.smoosy.atlas.jp/ja/instruction_for_authors)). Further information is available upon request.

Regarding the use of generative AI (such as ChatGPT): The use of generative AI when creating the manuscript to be submitted to MHC must be limited to proofreading. Submission of any manuscripts created by providing data is prohibited.

Types of papers published: Original articles, reviews, series, short communications (including research and technical bulletins) and case reports are acceptable.

Review: The editorial board is responsible for the acceptance of all submitted papers based on a review by multiple referees. Based on the outcome of the review, the board may request corrections, omissions, or additions for publication in MHC.

Copyright: Papers that are accepted for publication become copyright of JSHI and will be made available electronically via the J-Stage platform (<https://www.jstage.jst.go.jp/>).

Fees: There is no fee for publication. However, the authors will be responsible for the costs

incurred for special processing (please specify at submission if special processing is required).

Reprints: Reprints are not prepared, but pdf files can be obtained via the J-Stage platform (<https://www.jstage.jst.go.jp/>)..

## **Manuscript (in English)**

### **1. Original articles**

#### Summary

Articles are limited to 4,000 words. Each figure, table, and photograph must be included on separate manuscript pages and must include a title. The location of tables and figures in the manuscript must be clearly stated in the main text. The main text must be submitted as a Microsoft Word file, tables as a Microsoft Word, Excel, or PowerPoint files, and figures and photographs as PowerPoint files. All files must be electronically sent as attached files via email to the editor-in-chief at the editorial office. If the authors would like to submit large size files (over 100 MB), the large size files may be submitted via a high volume file transfer service. In that case, the authors must contact the editorial office (indicated on the last page of this instruction) before submission.

#### First page

The first page is the title page, which must clearly state that the submitted article is an "Original article" and include titles, and the name and affiliation of each author. Include the address, name, telephone number, fax number, and email address of the corresponding author at the bottom of the title page. Follow the example shown below for the title, author names, and affiliations:

#### **Susceptibility gene for non-obstructive azoospermia in the HLA class II region: correlations with Y chromosome microdeletion and spermatogenesis.**

Tetsuya Takao<sup>1)</sup>, Akira Tsujimura<sup>1)</sup>, Masaharu Sada<sup>2)</sup>, Reiko Goto<sup>2)</sup>, Minoru Koga<sup>3)</sup>, Yasushi Miyagawa<sup>1)</sup>, Kiyomi Matsumiya<sup>1)</sup>, Kazuhiko Yamada<sup>2)</sup>, Shiro Takahara<sup>1)</sup>

1) Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

2) Department of Regenerative Medicine, National Cardiovascular Center, Suita, Osaka, Japan

3) Department of Urology, Osaka Central Hospital, Osaka, Japan

Main text

- The second page must contain an "Abstract" no more than 250 words in length, followed by key words (no more than five).
- Starting on the third page, the main text begins with the "Introduction" and is followed by the "Materials and Methods", "Results", "Discussion", "Acknowledgments", "Conflict of Interest", and "References" sections, in this order.
- Geographic, human, and scientific names are listed in their original languages. Use generic names for drugs with commercial names in parentheses.
- Indicate units and quantities using Arabic numbers followed by international units (cm, ml, g, kg, pg, l, %, °C, etc.).

References

References should include names of authors (last names first); title of article; title of journal (abbreviate according to the style of *Index Medicus*) or book; volume number; location and name of publishing company (book only); first page, year of publication. For references with more than three authors, list the first three, followed by "et al.". See the examples below:

*Journal.*

Shi Y, Yoshihara F, Nakahama H, et al.: A novel immunosuppressant FTY720 ameliorates proteinuria and alterations of intrarenal adrenomedullin in rats with autoimmune glomerulonephritis. *Regulatory Peptides* 127: 233-238, 2005.

*Book.*

Katz DH: *Lymphocyte Differentiation, Recognition, and Regulation*. New York, Academic Press, 1997

*Chapter in a book.*

Tongio M, Abbal M, Bignon JD, et al. ASH#18 : HLA-DPB1.

Charron D (ed): *Genetic diversity of HLA Functional and Medical Implication*. Paris, EDK, 1997

## **2. Short communications (including research and technical bulletins) and Case reports**

### Summary

Short communications are limited to 1,500 words. For other information, please see the "Summary" section of "Original articles" described before.

### First page

The first page is the title page, which must clearly state that the submitted article is a "Short Communication" or "Case report" and include titles and the name and affiliation of each author. Include the address, name, telephone number, fax number, and e-mail address of the corresponding author at the bottom of the title page. Follow the example shown below for the title, author names, and affiliations:

### Main text

- Short communications and case reports do not require an abstract.
- After the second page, follow the same guidelines for the third and subsequent pages of original articles as described.

## **3. Reviews, Series, and Others**

As a general rule, reviews and series are written by invitation from the editorial board; however, submission by JSHI members is strongly encouraged. The editorial board determines the total number of pages, but in general a manuscript of no more than 3,000 words is preferable. As a general rule, reviews and series follow the format for original articles.

### **Editorial Office and Mailing Address**

Manuscripts should be submitted to the Editor-in-Chief at the Editorial office:

Editor-in-Chief: Yukari Kuroda

Email of Editorial office: [mhc.edit.office@soubun.org](mailto:mhc.edit.office@soubun.org)

## Check sheet on paper submission (enacted on Feb. 6, 2025)

### Declaration of no research misconduct (for authors from abroad only)

We declare that we have not engaged in any of the following research misconduct in the preparation of papers (original articles, reviews, series, short reports, case reports) to be submitted to MHC.

\*Please check the following appropriate boxes.

#### Specific research misconduct

- ☐ **Fabrication** (creating non-existent data, research results, etc.)
- ☐ **Falsification** (changing research materials, equipment, or processes to make data, results obtained through research activities inauthentic, etc.)
- ☐ **Plagiarism** (using idea of another researcher, analysis methods, data, research results, papers, or terminology without the consent of the relevant researcher or appropriate disclosure)

#### Research misconduct other than specific research misconduct

- ☐ **Duplicated submission** (submission of a paper that is essentially the same as a paper already published or submitted to another academic journal, etc., including storage in an institutional repository. However, this does not include abstracts for presentations at academic conferences, workshops, etc.)
- ☐ **Inappropriate authorship** (submitting a paper without properly disclosing the authorship of the paper): Inappropriate authorship includes "gift authorship" (listing someone who has not directly contributed to the paper as an author), "ghost authorship" (people who have made meaningful contributions to the research paper are not listed as co-authors), and "guest authorship" (inviting a well-known researcher in the relevant research field to be a co-author in order to gain an advantage in the review process)

**Regarding the use of generative AI (such as writing tools and ChatGPT)**

- ☐ No generative AI was used in creating the manuscript for submission to MHC.
- ☐ Generative AI was used in creating the manuscript for submission to MHC, but only for proofreading purpose.

Date: \_\_\_\_\_

Name of All authors: \_\_\_\_\_

Corresponding author's name: \_\_\_\_\_

Corresponding author's signature (self-signed): \_\_\_\_\_

\*After creating this checklist, convert it to a PDF and attach it to the paper on submission.